Biomarkers /
EGR1
Overview
EGR1 is altered in 0.85% of all cancers with diffuse large B-cell lymphoma, not otherwise specified, follicular lymphoma, multiple myeloma, classical hodgkin lymphoma, and conventional glioblastoma multiforme having the greatest prevalence of alterations [3].
The most common alterations in EGR1 are EGR1 Loss (0.17%), EGR1 P443S (0.13%), EGR1 Q95E (0.05%), EGR1 S66N (0.05%), and EGR1 S66T (0.05%) [3].
References
1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.
4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.